LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks

The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.

Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 43.7x to 48.7x.

AnalystConsensusTarget has decreased revenue growth from -19.6% to -28.7%, increased profit margin from 10.5% to 19.3%, increased future PE multiple from 38.9x to 43.7x and increased shares outstanding growth rate from 0.0% to 0.0%.